Five Pipeline Risks You Can't See in a Spreadsheet
Your pipeline report says $4.2M. Your forecast says you’ll close $1.8M this quarter. The numbers look reasonable. The coverage ratio is fine. And then the quarter ends $600K short, and everyone wants to know what happened.
What happened is that the risks were there the whole time — hiding in the shape of the pipeline, not the size of it. A list of deals sorted by amount or close date doesn’t show you concentration, timing, or realism problems. Those patterns only emerge visually. It’s exactly why we built the Health View in Pipeline Reviews — to make the shape of your pipeline impossible to ignore.
1. Concentration risk
One deal is 40% of your pipeline. It’s in Commit. The rep is confident. The forecast depends on it.
This is the most common pipeline risk and the hardest to feel in a list view. When you look at a sorted list, a $600K deal at the top doesn’t feel qualitatively different from the five $100K deals below it. But plotted as bubbles, the visual is unmistakable: one enormous circle dominates the chart, and everything else is small.
The question concentration risk forces you to ask: if this deal slips, what happens to the quarter? If the answer is “we miss,” that’s not a pipeline — it’s a bet.
What to do about it: Don’t just monitor the deal. Monitor the pipeline without the deal. If the rest of your pipeline can’t cover the number on its own, you need more pipeline, not more hope about the big one.
2. End-of-quarter stacking
Six deals have a close date of March 31st. Four more say March 28th. The last week of the quarter holds 60% of the pipeline.
Everyone knows this isn’t how deals actually close. Deals close when procurement signs, when legal finishes review, when the budget is approved — not because the calendar says it’s quarter-end. But reps default to the last day of the quarter because it’s the easiest close date to pick.
When you see the “snowman” — bubbles stacked vertically on the same date — you’re looking at forecast fiction. Some of those deals will close. Many will slip to the first week of next quarter. And the forecast gave you no warning because every deal technically had a close date inside the period.
What to do about it: Push for realistic close dates during deal reviews. If a deal is in Proposal stage with no signed contract and the close date is in five days, that close date is aspirational. Move it. The short-term pain of a lower forecast number is better than the quarter-end surprise.
3. Coverage gaps
You have deals closing in April. You have deals closing in June. May is empty.
A gap in the timeline is a future revenue drought — and it’s invisible in any report that doesn’t show deals on a timeline. In a list sorted by close date, you see April deals, then June deals, and your eye doesn’t register the absence of May.
In a visual chart, the gap is obvious: an empty stretch of timeline with no bubbles. That gap means either your team doesn’t have deals closing in May (a pipeline generation problem) or the deals that should close in May have been pushed to June (a slippage problem). Either way, you want to know now, not in May.
What to do about it: Investigate the gap early. Is there pipeline that should be closing in that window but isn’t? Did deals slip from there? Do you need to accelerate early-stage deals to fill the gap?
4. Stage stagnation
You have plenty of pipeline — but it’s all light blue. Early stage. Prospecting and qualification deals that haven’t progressed.
A pipeline chart where every bubble is the same light shade tells you that your deals aren’t moving through stages. The total amount might look healthy, but the conversion probability is low because nothing is far enough along to close this quarter.
The inverse pattern is also revealing: if everything is dark blue (late stage) but there’s very little light blue behind it, you have a pipeline generation problem. This quarter might be fine, but next quarter has nothing feeding it.
What to do about it: Stage progression should be part of your weekly review. Not just “what’s in the pipeline” but “what moved forward this week.” If deals are sitting in the same stage for weeks, something is broken — the deal, the rep’s process, or the stage definition.
5. The coverage illusion
Your pipeline-to-quota ratio is 3x. That looks healthy. But when you plot the pipeline visually, you realize that $2M of your $3M pipeline is two large deals in early stages, and the remaining $1M is a dozen small deals scattered across the quarter.
The coverage ratio said 3x. The reality is that you’re depending on two early-stage deals to make up two-thirds of your target. If those are the “3x coverage” leadership is relying on, the forecast is built on sand.
What to do about it: Look at coverage by stage, not just in total. How much of your coverage is in Commit? In Best Case? In early-stage Pipeline? A 3x ratio where most of the coverage is in Commit is very different from a 3x ratio where most of it is in Prospecting.
Why these risks hide
These patterns share something in common: they’re invisible in tabular data. A sorted list of deals shows you amounts and dates but not relationships between them. A dashboard with summary numbers shows you totals but not distribution.
Risk lives in the shape of the data, not the numbers. You need a visual to see shape.
The Health View in Akoonu Pipeline Reviews plots every deal by close date, amount, and stage — making concentration, timing, and coverage risks visible at a glance. See it on your pipeline.
